
Errata

The February 20, 2017, article by Choueiri et al, entitled “Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial” (J Clin Oncol 35: 591-597), was published with errors in Table 2.

The percentages for ORR have been corrected for cabozantinib and sunitinib. The number and percent of patients with

complete or partial responses or stable disease have also been corrected for cabozantinib and sunitinib.

The online version has been corrected in departure from the print. The authors apologize for the errors.

DOI: <https://doi.org/10.1200/JCO.2017.77.6526>; published February 10, 2018

The November 1, 2016, article by Giacalone et al, entitled “Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial” (J Clin Oncol 10.1200/JCO.2016.68.4530), was published with an error.

An **Acknowledgement** section should have been included with the following statement: “**This research was funded in**

part through the NIH/NCI Cancer Center Support Grant P30 CA008748.”

This has been corrected as of January 12, 2018. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.2017.77.6245>; published February 10, 2018

The December 10, 2017, article by Dreyling et al, entitled “Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma” (J Clin Oncol 10.1200/JCO.2017.75.4648), was published with an error.

The TOC category was listed as Prostate Cancer. It should have been **Hematologic Malignancy**.

This has been corrected as of January 12, 2018. *Journal of Clinical Oncology* apologizes for the error.

DOI: <https://doi.org/10.1200/JCO.2017.77.5718>; published February 10, 2018
